Resistance of Gram-Positive Bacteria to Current Antibacterial Agents and Overcoming Approaches

Rafik Karaman, Buthaina Jubeh, Zeinab Breijyeh, Rafik Karaman, Buthaina Jubeh, Zeinab Breijyeh

Abstract

The discovery of antibiotics has created a turning point in medical interventions to pathogenic infections, but unfortunately, each discovery was consistently followed by the emergence of resistance. The rise of multidrug-resistant bacteria has generated a great challenge to treat infections caused by bacteria with the available antibiotics. Today, research is active in finding new treatments for multidrug-resistant pathogens. In a step to guide the efforts, the WHO has published a list of the most dangerous bacteria that are resistant to current treatments and requires the development of new antibiotics for combating the resistance. Among the list are various Gram-positive bacteria that are responsible for serious healthcare and community-associated infections. Methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and drug-resistant Streptococcus pneumoniae are of particular concern. The resistance of bacteria is an evolving phenomenon that arises from genetic mutations and/or acquired genomes. Thus, antimicrobial resistance demands continuous efforts to create strategies to combat this problem and optimize the use of antibiotics. This article aims to provide a review of the most critical resistant Gram-positive bacterial pathogens, their mechanisms of resistance, and the new treatments and approaches reported to circumvent this problem.

Keywords: Gram-positive; MRSA; antibiotic; antimicrobial; bacteriophage; probiotic; resistance; β-lactam.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Diagram illustrating the cell wall structure of Gram-positive bacteria.
Figure 2
Figure 2
Mechanisms of resistance of Gram-positive bacteria.
Figure 3
Figure 3
Chemical structures of ceftaroline (1), ceftobiprole (2), tedizolid phosphate (3),besifloxacin (4), delafloxacin (5),ozenoxacin (6), and omadacycline (7).
Figure 4
Figure 4
Chemical structures of vancomycin (8), dalbavancin (9), telavancin (10), and oritavancin (11).
Figure 5
Figure 5
Chemical structures of teixobactin (12), malacidins (13), dodecyl 4,6-dideoxy-α-D-Xylo-hexopyranoside (14), cannabichromene (15), cannabigerol (16), cannabidiol (17), cannabinol (18), ∆9-tetrahydrocannabinol (19), DCAP (20), and Odilorhabdins (21).

References

    1. Davies J., Davies D. Origins and Evolution of Antibiotic Resistance. Microbiol. Mol. Boil. Rev. 2010;74:417–433. doi: 10.1128/MMBR.00016-10.
    1. Reygaert W. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol. 2018;4:482–501. doi: 10.3934/microbiol.2018.3.482.
    1. Cornaglia G. Fighting infections due to multidrug-resistant Gram-positive pathogens. Clin. Microbiol. Infect. 2009;15:209–211. doi: 10.1111/j.1469-0691.2009.02737.x.
    1. Asokan G.V., Ramadhan T., Ahmed E., Sanad H. WHO Global Priority Pathogens List: A Bibliometric Analysis of Medline-PubMed for Knowledge Mobilization to Infection Prevention and Control Practices in Bahrain. Oman Med. J. 2019;34:184–193. doi: 10.5001/omj.2019.37.
    1. Sizar O., Unakal C.G. Gram Positive Bacteria. StatPearls; Treasure Island, FL, USA: 2020.
    1. Silhavy T.J., Kahne D., Walker S. The Bacterial Cell Envelope. Cold Spring Harb. Perspect. Boil. 2010;2:a000414. doi: 10.1101/cshperspect.a000414.
    1. Yang D.C., Blair K.M., Salama N.R. Staying in Shape: The Impact of Cell Shape on Bacterial Survival in Diverse Environments. Microbiol. Mol. Boil. Rev. 2016;80:187–203. doi: 10.1128/MMBR.00031-15.
    1. Rajagopal M., Walker S.G. Envelope Structures of Gram-Positive Bacteria. Volume 404. Springer Science and Business Media LLC; Berlin/Heidelberg, Germany: 2017. pp. 1–44.
    1. Munita J.M., Bayer A.S., Arias C.A. Evolving resistance among Gram-positive pathogens. Clin. Infect. Dis. 2015;61:S48–S57. doi: 10.1093/cid/civ523.
    1. Berger-Bächi B. Resistance mechanisms of Gram-positive bacteria. Int. J. Med Microbiol. 2002;292:27–35. doi: 10.1078/1438-4221-00185.
    1. Fisher J.F., Mobashery S. Beta-Lactam Resistance Mechanisms: Gram-Positive Bacteria and Mycobacterium tuberculosis. Cold Spring Harb. Perspect. Med. 2016;6 doi: 10.1101/cshperspect.a025221.
    1. Kapoor G., Saigal S., Elongavan A. Action and resistance mechanisms of antibiotics: A guide for clinicians. J. Anaesthesiol. Clin. Pharmacol. 2017;33:300–305. doi: 10.4103/joacp.JOACP_349_15.
    1. Sujatha S., Praharaj I. Glycopeptide Resistance in Gram-Positive Cocci: A Review. Interdiscip. Perspect. Infect. Dis. 2012;2012:1–10. doi: 10.1155/2012/781679.
    1. Aldred K.J., Kerns R.J., Osheroff N. Mechanism of Quinolone Action and Resistance. Biochemistry. 2014;53:1565–1574. doi: 10.1021/bi5000564.
    1. Hooper D.C. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect. Dis. 2002;2:530–538. doi: 10.1016/S1473-3099(02)00369-9.
    1. Krause K.M., Serio A.W., Kane T.R., Connolly L.E. Aminoglycosides: An Overview. Cold Spring Harb. Perspect. Med. 2016;6:a027029. doi: 10.1101/cshperspect.a027029.
    1. Pechère J.-C. Macrolide resistance mechanisms in Gram-positive cocci. Int. J. Antimicrob. Agents. 2001;18:25–28. doi: 10.1016/S0924-8579(01)00407-1.
    1. Dweba C., Zishiri O.T., El Zowalaty M.E. Methicillin-resistant Staphylococcus aureus: Livestock-associated, antimicrobial, and heavy metal resistance. Infect. Drug Resist. 2018;11:2497–2509. doi: 10.2147/IDR.S175967.
    1. Tong S.Y.C., Davis J.S., Eichenberger E., Holland T.L., Fowler V.G. Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management. Clin. Microbiol. Rev. 2015;28:603–661. doi: 10.1128/CMR.00134-14.
    1. Chambers H.F., deLeo F.R. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Genet. 2009;7:629–641. doi: 10.1038/nrmicro2200.
    1. Crisóstomo M.I., Westh H., Tomasz A., Chung M., Oliveira D., de Lencastre H. The evolution of methicillin resistance in Staphylococcus aureus: Similarity of genetic backgrounds in historically early methicillin-susceptible and -resistant isolates and contemporary epidemic clones. Proc. Natl. Acad. Sci. USA. 2001;98:9865–9870. doi: 10.1073/pnas.161272898.
    1. Pantosti A., Sanchini A., Monaco M. Mechanisms of antibiotic resistance inStaphylococcus aureus. Futur. Microbiol. 2007;2:323–334. doi: 10.2217/17460913.2.3.323.
    1. David M.Z., Glikman D., Crawford S.E., Peng J., King K.J., Hostetler M.A., Boyle-Vavra S., Daum R.S. What Is Community-Associated Methicillin-Resistant Staphylococcus aureus? J. Infect. Dis. 2008;197:1235–1243. doi: 10.1086/533502.
    1. Sieradzki K., Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J. Bacteriol. 1997;179:2557–2566. doi: 10.1128/JB.179.8.2557-2566.1997.
    1. Cui L., Iwamoto A., Lian J.-Q., Neoh H.-M., Maruyama T., Horikawa Y., Hiramatsu K. Novel Mechanism of Antibiotic Resistance Originating in Vancomycin-Intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 2006;50:428–438. doi: 10.1128/AAC.50.2.428-438.2006.
    1. Tanaka M., Wang T., Onodera Y., Uchida Y., Sato K. Mechanism of quinolone resistance in Staphylococcus aureus. J. Infect. Chemother. 2000;6:131–139. doi: 10.1007/s101560070010.
    1. Foster T. Antibiotic resistance in Staphylococcus aureus. Status and prospects. FEMS Microbiol. Rev. 2017;41:430–449. doi: 10.1093/femsre/fux007.
    1. Bayer A.S., Schneider T., Sahl H.-G. Mechanisms of daptomycin resistance in Staphylococcus aureus: Role of the cell membrane and cell wall. Ann. New York Acad. Sci. 2012;1277:139–158. doi: 10.1111/j.1749-6632.2012.06819.x.
    1. Miller W.R., Bayer A.S., Arias C.A. Mechanism of Action and Resistance to Daptomycin in Staphylococcus aureus and Enterococci. Cold Spring Harb. Perspect. Med. 2016;6:a026997. doi: 10.1101/cshperspect.a026997.
    1. Babaoglu K., Qi J., Lee R.E., White S.W. Crystal Structure of 7,8-Dihydropteroate Synthase from Bacillus anthracis. Struct. 2004;12:1705–1717. doi: 10.1016/j.str.2004.07.011.
    1. Rouch D.A., Messerotti L.J., Loo L.S.L., Jackson C.A., Skurray R.A. Trimethoprim resistance transposon Tn4003 from Staphylococcus aureus encodes genes for a dihydrofolate reductase and thymidylate synthetase flanked by three copies of IS257. Mol. Microbiol. 1989;3:161–175. doi: 10.1111/j.1365-2958.1989.tb01805.x.
    1. Emaneini M., Bigverdi R., Kalantar D., Soroush S., Jabalameli F., Khoshgnab B.N., Asadollahi P., Taherikalani M. Distribution of genes encoding tetracycline resistance and aminoglycoside modifying enzymes in Staphylococcus aureus strains isolated from a burn center. Ann. Burn. Fire Disasters. 2013;26:76–80.
    1. Prabhu K., Rao S., Rao I.V. Inducible Clindamycin Resistance in Staphylococcus aureus Isolated from Clinical Samples. J. Lab. Phys. 2011;3:025–027. doi: 10.4103/0974-2727.78558.
    1. Cetinkaya Y., Falk P., Mayhall C.G. Vancomycin-resistant enterococci. Clin. Microbiol. Rev. 2000;13:686–707. doi: 10.1128/CMR.13.4.686.
    1. Lee T., Pang S., Abraham S., Coombs G.W. Antimicrobial-resistant CC17 Enterococcus faecium: The past, the present and the future. J. Glob. Antimicrob. Resist. 2019;16:36–47. doi: 10.1016/j.jgar.2018.08.016.
    1. Miller W.R., Munita J.M., Arias C.A. Mechanisms of antibiotic resistance in enterococci. Expert Rev. Anti-Infect.Ther. 2014;12:1221–1236. doi: 10.1586/14787210.2014.956092.
    1. Fontana R., Aldegheri M., Ligozzi M., Lopez H., Sucari A., Satta G. Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in Enterococcus faecium. Antimicrob. Agents Chemother. 1994;38:1980–1983. doi: 10.1128/AAC.38.9.1980.
    1. Rubinstein E., Keynan Y. Vancomycin-resistant enterococci. Crit. Care Clin. 2013;29:841–852. doi: 10.1016/j.ccc.2013.06.006.
    1. Cattoir V., Giard J.-C. Antibiotic resistance in Enterococcus faecium clinical isolates. Exp. Rev. Anti-Infect. Ther. 2014;12:239–248. doi: 10.1586/14787210.2014.870886.
    1. Zivich P.N., Grabenstein J.D., Becker-Dreps S.I., Weber D.J. Streptococcus pneumoniae outbreaks and implications for transmission and control: A systematic review. Pneumonia. 2018;10:11. doi: 10.1186/s41479-018-0055-4.
    1. Mamishi S., Moradkhani S., Mahmoudi S., Sadeghi R.H., Pourakbari B. Penicillin-Resistant trend of Streptococcus pneumoniae in Asia: A systematic review. Iran. J. Microbiol. 2014;6:198–210.
    1. Hampton L.M., Farley M.M., Schaffner W., Thomas A., Reingold A., Harrison L.H., Lynfield R., Bennett N.M., Petit S., Gershman K., et al. Prevention of Antibiotic-Nonsusceptible Streptococcus pneumoniaeWith Conjugate Vaccines. J. Infect. Dis. 2011;205:401–411. doi: 10.1093/infdis/jir755.
    1. Kim L., McGee L., Tomczyk S., Beall B. Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: A United States Perspective. Clin. Microbiol. Rev. 2016;29:525–552. doi: 10.1128/CMR.00058-15.
    1. Jacobs M.R. Drug-resistant Streptococcus pneumoniae: Rational antibiotic choices. Am. J. Med. 1999;106:19–25. doi: 10.1016/S0002-9343(98)00351-9.
    1. Wang E.E., Kellner J.D., Arnold S. Antibiotic-resistant Streptococcus pneumoniae. Implications for medical practice. Can. Fam. Phys. Med. Fam. Can. 1998;44:1881–1888.
    1. Reinert R. The antimicrobial resistance profile of Streptococcus pneumoniae. Clin. Microbiol. Infect. 2009;15:7–11. doi: 10.1111/j.1469-0691.2009.02724.x.
    1. Namvar A.E., Bastarahang S., Abbasi N., Ghehi G.S., Farhadbakhtiarian S., Arezi P., Hosseini M., Baravati S.Z., Jokar Z., Chermahin S.G. Clinical characteristics of Staphylococcus epidermidis: A systematic review. GMS Hyg. Infect. Control. 2014;9:23.
    1. Lo D., Shieh H.H., Barreira E.R., Ragazzi S.L.B., Gilio A.E. High Frequency of Staphylococcus saprophyticus Urinary Tract Infections Among Female Adolescents. Pediatr. Infect. Dis. J. 2015;34:1025. doi: 10.1097/INF.0000000000000780.
    1. Chun S., Huh H.J., Lee N.Y. Species-Specific Difference in Antimicrobial Susceptibility Among Viridans Group Streptococci. Ann. Lab. Med. 2015;35:205–211. doi: 10.3343/alm.2015.35.2.205.
    1. Nakajima T., Nakanishi S., Mason C., Montgomery J., Leggett P., Matsuda M., Coulter W.A., Millar B.C., Goldsmith C.E., Moore J.E. Population structure and characterization of viridans group streptococci (VGS) isolated from the upper respiratory tract of patients in the community. Ulst. Med. J. 2013;82:164–168.
    1. Chen Z., Itzek A., Malke H., Ferretti J.J., Kreth J. Multiple Roles of RNase Y in Streptococcus pyogenes mRNA Processing and Degradation. J. Bacteriol. 2013;195:2585–2594. doi: 10.1128/JB.00097-13.
    1. Bolukaoto J.Y., Monyama C.M., Chukwu M.O., Lekala L.M., Nchabeleng M., Maloba M.R.B., Mavenyengwa R.T., Lebelo S.L., Monokoane S., Tshepuwane C., et al. Antibiotic resistance of Streptococcus agalactiae isolated from pregnant women in Garankuwa, South Africa. BMC Res. Notes. 2015;8:364. doi: 10.1186/s13104-015-1328-0.
    1. Spigaglia P. Recent advances in the understanding of antibiotic resistance inClostridium difficileinfection. Ther. Adv. Infect. Dis. 2015;3:23–42. doi: 10.1177/2049936115622891.
    1. Chon J.-W., Seo K.-H., Bae D., Park J.-H., Khan S., Sung K. Prevalence, toxin gene profile, antibiotic resistance, and molecular characterization of Clostridium perfringens from diarrheic and non-diarrheic dogs in Korea. J. Veter Sci. 2018;19:368–374. doi: 10.4142/jvs.2018.19.3.368.
    1. Hamza D., Dorgham S., Hakim A. Toxinotyping and Antimicrobial Resistance of Clostridium Perfringens Isolated from Processed Chicken Meat Products. J. Veter. Res. 2017;61:53–58. doi: 10.1515/jvetres-2017-0007.
    1. Helgason E., Økstad O.A., Caugant D.A., Johansen H.A., Fouet A., Mock M., Hegna I., Kolstø A.-B. Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis—One Species on the Basis of Genetic Evidence. Appl. Environ. Microbiol. 2000;66:2627–2630. doi: 10.1128/AEM.66.6.2627-2630.2000.
    1. Loesche W.J. Medical Microbiology. 4th ed. University of Texas Medical Branch at Galveston; Galveston, TX, USA: 1996. Microbiology of dental decay and periodontal disease.
    1. Trost E., Blom J., Soares S.C., Huang I.-H., Al-Dilaimi A., Schröder J., Jaenicke S., Dorella F.A., Rocha F., Miyoshi A., et al. Pangenomic Study of Corynebacteriumdiphtheriae That Provides Insights into the Genomic Diversity of Pathogenic Isolates from Cases of Classical Diphtheria, Endocarditis, and Pneumonia. J. Bacteriol. 2012;194:3199–3215. doi: 10.1128/JB.00183-12.
    1. Morvan A., Moubareck C., Leclercq A., Hervé-Bazin M., Bremont S., Lecuit M., Courvalin P., le Monnier A. Antimicrobial Resistance of Listeria monocytogenes Strains Isolated from Humans in France. Antimicrob. Agents Chemother. 2010;54:2728–2731. doi: 10.1128/AAC.01557-09.
    1. Kinney K.K. Treatment of Infections Caused By Antimicrobial-Resistant Gram-Positive Bacteria. Am. J. Med. Sci. 2010;340:209–217. doi: 10.1097/MAJ.0b013e3181e99aa4.
    1. Morosini M.-I., Díez-Aguilar M., Cantón R. Mechanisms of action and antimicrobial activity of ceftobiprole. Rev. Esp.Quimioter. 2019;32:3–10.
    1. Koulenti D., Xu E., Mok I.Y.S., Song A., Karageorgopoulos D.E., Armaganidis A., Lipman J., Tsiodras S. Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms. 2019;7:270. doi: 10.3390/microorganisms7080270.
    1. Rybak J.M., Roberts K. Tedizolid Phosphate: A Next-Generation Oxazolidinone. Infect. Dis. Ther. 2015;4:1–14. doi: 10.1007/s40121-015-0060-3.
    1. Burgos R.M., Rodvold K.A. Omadacycline: A novel aminomethylcycline. Infect. Drug Resist. 2019;12:1895–1915. doi: 10.2147/IDR.S171352.
    1. Gallagher J. Omadacycline: A Modernized Tetracycline. Clin. Infect. Dis. 2019;69:S1–S5. doi: 10.1093/cid/ciz394.
    1. Zhanel G.G., Calic D., Schweizer F., Zelenitsky S.A., Adam H., Lagacé-Wiens P.R.S., Rubinstein E., Gin A.S., Hoban D.J., Karlowsky J.A., et al. New Lipoglycopeptides. Drugs. 2010;70:859–886. doi: 10.2165/11534440-000000000-00000.
    1. Ling L.L., Schneider T., Peoples A.J., Spoering A.L., Engels I., Conlon B.P., Müller A., Schäberle T.F., Hughes D.E., Epstein S., et al. A new antibiotic kills pathogen without detectable resistance. Nature. 2015;517:455–459. doi: 10.1038/nature14098.
    1. McCarthy M.W. Teixobactin: A novel anti-infective agent. Expert Rev. Anti-Infect. Ther. 2018;17:1–3. doi: 10.1080/14787210.2019.1550357.
    1. Hover B.M., Kim S.-H., Katz M., Charlop-Powers Z., Owen J.G., Ternei M.A., Maniko J., Estrela A.B., Molina H., Park S., et al. Culture-independent discovery of the malacidins as calcium-dependent antibiotics with activity against multidrug-resistant Gram-positive pathogens. Nat. Microbiol. 2018;3:415–422. doi: 10.1038/s41564-018-0110-1.
    1. James G., Swogger E., Wolcott R., Pulcini E.D., Secor P., Sestrich J., Costerton J.W., Stewart P.S. Biofilms in chronic wounds. Wound Repair Regen. 2008;16:37–44. doi: 10.1111/j.1524-475X.2007.00321.x.
    1. Lai Y., Gallo R.L. AMPed up immunity: How antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009;30:131–141. doi: 10.1016/j.it.2008.12.003.
    1. Bahar A., Ren D. Antimicrobial peptides. Pharmaceuticals. 2013;6:1543–1575. doi: 10.3390/ph6121543.
    1. Chung P.Y., Khanum R. Antimicrobial peptides as potential anti-biofilm agents against multidrug-resistant bacteria. J. Microbiol. Immunol. Infect. 2017;50:405–410. doi: 10.1016/j.jmii.2016.12.005.
    1. Zhou Y., Peng Y. Synergistic effect of clinically used antibiotics and peptide antibiotics against Gram-positive and Gram-negative bacteria. Exp. Ther. Med. 2013;6:1000–1004. doi: 10.3892/etm.2013.1231.
    1. Pouny Y., Rapaport D., Mor A., Nicolas P., Shai Y. Interaction of antimicrobial dermaseptin and its fluorescently labeled analogs with phospholipid membranes. Biochemistry. 1992;31:12416–12423. doi: 10.1021/bi00164a017.
    1. Yang L., Harroun T.A., Weiss T.M., Ding L., Huang H.W. Barrel-stave model, or toroidal model? A case study on melittin pores. Biophys. J. 2001;81:1475–1485. doi: 10.1016/S0006-3495(01)75802-X.
    1. Kaconis Y., Kowalski I., Howe J., Brauser A., Richter W., Razquin-Olazarán I., Íñigo M., Garidel P., Rössle M., de Tejada G.M., et al. Biophysical Mechanisms of Endotoxin Neutralization by Cationic Amphiphilic Peptides. Biophys. J. 2011;100:2652–2661. doi: 10.1016/j.bpj.2011.04.041.
    1. Matsuzaki K., Murase O., Fujii N., Miyajima K. An Antimicrobial Peptide, Magainin 2, Induced Rapid Flip-Flop of Phospholipids Coupled with Pore Formation and Peptide Translocation. Biochemistry. 1996;35:11361–11368. doi: 10.1021/bi960016v.
    1. Samy R.P., Stiles B.G., Franco O.L., Sethi G., Lim L. Animal venoms as antimicrobial agents. Biochem. Pharmacol. 2017;134:127–138. doi: 10.1016/j.bcp.2017.03.005.
    1. Yoon K.A., Yoon K.A., Yoon K.A. Differential Properties of Venom Peptides and Proteins in Solitary vs. Social Hunting Wasps. Toxins. 2016;8:32. doi: 10.3390/toxins8020032.
    1. Souza B.M., Mendes M.A., dos Santos L.D., Marques M.R., César L.M., Almeida R.N., Pagnocca F.C., Konno K., Palma M.S. Structural and functional characterization of two novel peptide toxins isolated from the venom of the social wasp Polybiapaulista. Peptides. 2005;26:2157–2164. doi: 10.1016/j.peptides.2005.04.026.
    1. Wang K., Yan J., Chen R., Dang W., Zhang B., Zhang W., Song J., Wang R. Membrane-Active Action Mode of Polybia-CP, a Novel Antimicrobial Peptide Isolated from the Venom of Polybiapaulista. Antimicrob. Agents Chemother. 2012;56:3318–3323. doi: 10.1128/AAC.05995-11.
    1. Torres M.D.T., Pedron C.N., Higashikuni Y., Kramer R.M., Cardoso M.H., Oshiro K.G.N., Franco O.L., Junior P.I.S., Silva F.D., Junior V.X.O., et al. Structure-function-guided exploration of the antimicrobial peptide polybia-CP identifies activity determinants and generates synthetic therapeutic candidates. Commun. Boil. 2018;1:221. doi: 10.1038/s42003-018-0224-2.
    1. Das Neves R.C., Mortari M.R., Schwartz E.F., Kipnis A., Junqueira-Kipnis A.P. Antimicrobial and Antibiofilm Effects of Peptides from Venom of Social Wasp and Scorpion on Multidrug-Resistant Acinetobacterbaumannii. Toxins. 2019;11:216. doi: 10.3390/toxins11040216.
    1. Gomes B., Augusto M., Felício M.R., Hollmann A., Franco O.L., Gonçalves S., Santos N.C. Designing improved active peptides for therapeutic approaches against infectious diseases. Biotechnol. Adv. 2018;36:415–429. doi: 10.1016/j.biotechadv.2018.01.004.
    1. Dias C., Pais J.P., Nunes R., Blazquez-Sanchez M.T., Marquês J.T., Almeida A.F., Serra P., Xavier N.M., Vila-Viçosa D., Machuqueiro M., et al. Sugar-based bactericides targeting phosphatidylethanolamine-enriched membranes. Nat. Commun. 2018;9:4857. doi: 10.1038/s41467-018-06488-4.
    1. Martins A., Santos M.S.C., Dias C., Serra P., Cachatra V., Pais J., Caio J., Teixeira V., Machuqueiro M., Silva M.S., et al. Tuning the Bioactivity of TensioactiveDeoxy Glycosides to Structure: Antibacterial Activity Versus Selective Cholinesterase Inhibition Rationalized by Molecular Docking. Eur. J. Org. Chem. 2013:1448–1459. doi: 10.1002/ejoc.201201520.
    1. Baulamycins A.B. Broad-spectrum antibiotics identified as inhibitors of siderophore biosynthesis in Staphylococcus aureus and Bacillus anthracisTripathi. Ashootosh. 2006;49
    1. Appendino G., Gibbons S., Giana A., Pagani A., Grassi G., Stavri M., Smith E., Rahman M.M. Antibacterial Cannabinoids fromCannabis sativa: A Structure−Activity Study. J. Nat. Prod. 2008;71:1427–1430. doi: 10.1021/np8002673.
    1. Chakraborty S., Afaq N., Singh N., Majumdar S. Antimicrobial activity of Cannabis sativa, Thujaorientalis and Psidiumguajava leaf extracts against methicillin-resistant Staphylococcus aureus. J. Integr. Med. 2018;16:350–357. doi: 10.1016/j.joim.2018.07.005.
    1. Thanbichler M., Shapiro L. MipZ, a Spatial Regulator Coordinating Chromosome Segregation with Cell Division in Caulobacter. Cell. 2006;126:147–162. doi: 10.1016/j.cell.2006.05.038.
    1. Eun Y.J., Foss M.H., Kiekebusch D., Pauw D.A., Westler W.M., Thanbichler M., Weibel D.B. DCAP: A Broad-Spectrum Antibiotic That Targets the Cytoplasmic Membrane of Bacteria. J. Am. Chem. Soc. 2012;134:11322–11325. doi: 10.1021/ja302542j.
    1. Heinrich V., Hurley K., Santos T., Weibel D. DCAP: A broad-spectrum antibiotic that targets the cytoplasmic membrane of bacteria. FASEB J. 2015;29:575.
    1. Hurley K.A., Heinrich V., Hershfield J.R., Demons S.T., Weibel D.B. Membrane-Targeting DCAP Analogues with Broad-Spectrum Antibiotic Activity against Pathogenic Bacteria. ACS Med. Chem. Lett. 2015;6:466–471. doi: 10.1021/acsmedchemlett.5b00024.
    1. Pantel L., Florin T., Dobosz-Bartoszek M., Racine E., Sarciaux M., Serri M., Houard J., Campagne J.-M., de Figueiredo R.M., Midrier C., et al. Odilorhabdins, Antibacterial Agents that Cause Miscoding by Binding at a New Ribosomal Site. Mol. Cell. 2018;70:83–94.e7. doi: 10.1016/j.molcel.2018.03.001.
    1. Polikanov Y.S., Aleksashin N.A., Beckert B., Wilson D.N. The Mechanisms of Action of Ribosome-Targeting Peptide Antibiotics. Front. Mol. Biosci. 2018;5:48. doi: 10.3389/fmolb.2018.00048.
    1. d’Herelle F. Sur un microbe invisible antagoniste des bacillesdysentériques. CR Acad. Sci. Paris. 1917;165:373–375.
    1. Schultz E.W. One hundred patients with Staphylococcus septicemia receiving bacteriophage service. Calif. West. Med. 1929;31:5–10.
    1. MacNeal W.J., Frisbee F.C. A review of phage therapy against bacterial pathogens of aquatic and terrestrial organisms. Am. J. Med. Sci. 1936;191:179–195. doi: 10.1097/00000441-193602000-00004.
    1. Doss J., Culbertson K., Hahn D., Camacho J., Barekzi N. A Review of Phage Therapy against Bacterial Pathogens of Aquatic and Terrestrial Organisms. Viruses. 2017;9:50. doi: 10.3390/v9030050.
    1. Doolittle M.M., Cooney J.J., Caldwell D.E. Tracing the interaction of bacteriophage with bacterial biofilms using fluorescent and chromogenic probes. J. Ind. Microbiol. Biotechnol. 1996;16:331–341. doi: 10.1007/BF01570111.
    1. Parasion S., Kwiatek M., Gryko R., Mizak L., Malm A. Bacteriophages as an Alternative Strategy for Fighting Biofilm Development. Pol. J. Microbiol. 2014;63:137–145. doi: 10.33073/pjm-2014-019.
    1. Kortright K.E., Chan B.K., Koff J.L., Turner P.E. Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria. Cell Host Microbe. 2019;25:219–232. doi: 10.1016/j.chom.2019.01.014.
    1. Chanishvili N., Aminov R.I. Bacteriophage therapy: Coping with the growing antibiotic resistance problem. Microbiol. Aust. 2019;40:5. doi: 10.1071/MA19011.
    1. Kumaran D., Taha M., Yi Q., Ramirez-Arcos S., Diallo J.-S., Carli A., Abdelbary H. Does Treatment Order Matter? Investigating the Ability of Bacteriophage to Augment Antibiotic Activity against Staphylococcus aureus Biofilms. Front. Microbiol. 2018;9:127. doi: 10.3389/fmicb.2018.00127.
    1. Hill C., Guarnef F., Gibson G.R. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014;11:506–514. doi: 10.1038/nrgastro.2014.66.
    1. Hotel A.C.P., Cordoba A. Health, and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Prevention. 2001;5:1–10.
    1. Ouwehand A.C., Forssten S., Hibberd A., Lyra A., Stahl B. Probiotic approach to prevent antibiotic resistance. Ann. Med. 2016;48:1–10. doi: 10.3109/07853890.2016.1161232.
    1. Applegate J.A., Walker C.L.F., Ambikapathi R., Black R.E. Systematic review of probiotics for the treatment of community-acquired acute diarrhea in children. BMC Public Heal. 2013;13:S16. doi: 10.1186/1471-2458-13-S3-S16.
    1. Newberry S.J., Hempel S., Maher A.R., Wang Z., Miles J.N.V., Shanman R., Johnsen B., Shekelle P.G. Probiotics for the Prevention and Treatment of Antibiotic-Associated Diarrhea. JAMA. 2012;307:1959. doi: 10.1001/jama.2012.3507.
    1. King S., Glanville J., Sanders M.E., Fitzgerald A., Varley D. Effectiveness of probiotics on the duration of illness in healthy children and adults who develop common acute respiratory infectious conditions: A systematic review and meta-analysis. Br. J. Nutr. 2014;112:41–54. doi: 10.1017/S0007114514000075.
    1. Wang J., Ji H., Wang S., Liu H., Zhang W., Zhang N., Wang Y. Probiotic Lactobacillus plantarum Promotes Intestinal Barrier Function by Strengthening the Epithelium and Modulating Gut Microbiota. Front. Microbiol. 2018;9 doi: 10.3389/fmicb.2018.01953.
    1. de Vuyst L., Leroy F. Bacteriocins from Lactic Acid Bacteria: Production, Purification, and Food Applications. J. Mol. Microbiol. Biotechnol. 2007;13:194–199. doi: 10.1159/000104752.
    1. Ennahar S., Sashihara T., Sonomoto K., Ishizaki A. Class IIabacteriocins: Biosynthesis, structure, and activity. FEMS Microbiol. Rev. 2000;24:85–106. doi: 10.1111/j.1574-6976.2000.tb00534.x.
    1. Atassi F., Servin A.L. Individual and co-operative roles of lactic acid and hydrogen peroxide in the killing activity of enteric strain Lactobacillus johnsonii NCC933 and vaginal strain Lactobacillus gasseri KS120.1 against enteric, uropathogenic and vaginosis-associated pathog. FEMS Microbiol. Lett. 2010;304:29–38. doi: 10.1111/j.1574-6968.2009.01887.x.
    1. Midolo P.D., Lambert J.R., Hull R., Luo F., Grayson M.L. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J. Appl. Bacteriol. 1995;79:475–479. doi: 10.1111/j.1365-2672.1995.tb03164.x.
    1. Lin X., Chen X., Chen Y., Jiang W., Chen H. The effect of five probiotic lactobacilli strains on the growth and biofilm formation of S treptococcusmutans. Oral Dis. 2015;21:e128–e134. doi: 10.1111/odi.12257.
    1. Haller D., Bode C., Hammes W.P. Cytokine secretion by stimulated monocytes depends on the growth phase and heat treatment of bacteria: A comparative study between lactic acid bacteria and invasive pathogens. Microbiol. Immunol. 1999;43:925–935. doi: 10.1111/j.1348-0421.1999.tb03353.x.
    1. Tejada-Simon M.V., Pestka J.J. Proinflammatory Cytokine and Nitric Oxide Induction in Murine Macrophages by Cell Wall and Cytoplasmic Extracts of Lactic Acid Bacteria. J. Food Prot. 1999;62:1435–1444. doi: 10.4315/0362-028X-62.12.1435.
    1. Hessle C., Hanson L.A., Wold A. Lactobacilli from human gastrointestinal mucosa are strong stimulators of IL-12 production. Clin. Exp. Immunol. 1999;116:276–282. doi: 10.1046/j.1365-2249.1999.00885.x.
    1. Perdigon G., Alvarez S., Holgado A.P.D.R. Immunoadjuvant activity of oralLactobacilluscasei: Influence of dose on the secretory immune response and protective capacity in intestinal infections. J. Dairy Res. 1991;58:485–496. doi: 10.1017/S0022029900030090.
    1. Stone S.P., Fuller C., Savage J., Cookson B., Hayward A., Cooper B., Duckworth G., Michie S., Murray M., Jeanes A., et al. Evaluation of the national Cleanyourhands campaign to reduce Staphylococcus aureus bacteraemia and Clostridium difficile infection in hospitals in England and Wales by improved hand hygiene: Four year, prospective, ecological, interrupted time series study. BMJ. 2012;344:e3005. doi: 10.1136/bmj.e3005.
    1. Schwaber M.J., Lev B., Israeli A., Solter E., Smollan G., Rubinovitch B., Shalit I., Carmeli Y. Containment of a Country-wide Outbreak of Carbapenem-Resistant Klebsiellapneumoniae in Israeli Hospitals via a Nationally Implemented Intervention. Clin. Infect. Dis. 2011;52:848–855. doi: 10.1093/cid/cir025.
    1. Brinsley K., Srinivasan A., Sinkowitz-Cochran R., Lawton R., McIntyre R. Implementation of the campaign to prevent antimicrobial resistance in healthcare settings: I2 steps to prevent antimicrobial resistance among hospitalized adults-experiences from 3 institutions. Am. J. Infect. Control. 2005;33:53–54. doi: 10.1016/j.ajic.2004.12.003.
    1. Johnson A.P. Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: The first 10 years. J. Antimicrob. Chemother. 2012;67:802–809. doi: 10.1093/jac/dkr561.
    1. Laxminarayan R., Duse A., Wattal C., Zaidi A.K.M., Wertheim H.F.L., Sumpradit N., Vlieghe E., Hara G.L., Gould I.M., Goossens H., et al. Antibiotic resistance—The need for global solutions. Lancet Infect. Dis. 2013;13:1057–1098. doi: 10.1016/S1473-3099(13)70318-9.
    1. Winters C., Gelband H. Part I. The global antibiotic resistance partnership (GARP) SAMJ South Afr. Med. J. 2011;101:556–557.
    1. Sirijatuphat R., Sripanidkulchai K., Boonyasiri A., Rattanaumpawan P., Supapueng O., Kiratisin P., Thamlikitkul V. Implementation of global antimicrobial resistance surveillance system (GLASS) in patients with bacteremia. PLoS ONE. 2018;13:e0190132. doi: 10.1371/journal.pone.0190132.
    1. Aslam B., Wang W., Arshad M.I., Khurshid M., Muzammil S., Rasool M.H., Nisar M.A., Alvi R.F., Aslam M.A., Qamar M.U., et al. Antibiotic resistance: A rundown of a global crisis. Infect. Drug Resist. 2018;11:1645–1658. doi: 10.2147/IDR.S173867.
    1. Lee C.-R., Lee J.H., Kang L.-W., Jeong B.C., Lee S.H. Educational Effectiveness, Target, and Content for Prudent Antibiotic Use. BioMed Res. Int. 2015;2015:1–13. doi: 10.1155/2015/214021.
    1. Price L., Gozdzielewska L., Young M., Smith F., Macdonald J., McParland J., Williams L., Langdridge D., Davis M.D.M., Flowers P. Effectiveness of interventions to improve the public’s antimicrobial resistance awareness and behaviours associated with prudent use of antimicrobials: A systematic review. J. Antimicrob. Chemother. 2018;73:1464–1478. doi: 10.1093/jac/dky076.
    1. de Bont E.G.P.M., Alink M., Falkenberg F.C.J., Dinant G.-J., Cals J. Patient information leaflets to reduce antibiotic use and reconsultation rates in general practice: A systematic review. BMJ Open. 2015;5 doi: 10.1136/bmjopen-2015-007612.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren